immunotherapy

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…

5 months ago

Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method

Nes-Ziona, Israel, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

5 months ago

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Bria-Pros+ Activates Multiple Immune Cell Types Figure 1 shows that Bria-Pros+ activates a range of immune cells in a modified…

5 months ago

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing…

5 months ago

Ludwig Enterprises mRNA Bladder Cancer Study to be Launched

SPARKS, NV / ACCESSWIRE / January 31, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased…

5 months ago

High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies

                Press Release High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team…

5 months ago

ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ACARIZAX® (house dust mite…

6 months ago

Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population

TURKU, Finland and BOSTON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage…

6 months ago

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

Tailored Vaccines: With the AI-Immunology™ enabled discovery of these novel types of cancer vaccine targets, designing personalized and precision vaccine…

6 months ago